dc.contributor
Institut Català de la Salut
dc.contributor
[Casartelli C, Tommasi C, Lazzarin A, Corianò M, Serra O] Department of Medicine and Surgery, University of Parma, Parma, Italy. Medical Oncology Unit, University Hospital of Parma, Parma, Italy. Gruppo Oncologico Italiano di Ricerca Clinica (GOIRC), Parma, Italy. [Tornali C] Department of Medicine and Surgery, University of Parma, Parma, Italy. [Gutiérrez-Enríquez S] Hereditary Cancer Genetics Group, Vall d’Hebron Institute of Oncology (VHIO), Barcelona, Spain. [Llop-Guevara A, Serra V] Experimental Therapeutics Group, Vall d’Hebron Institute of Oncology (VHIO), Barcelona, Spain
dc.contributor
Vall d'Hebron Barcelona Hospital Campus
dc.contributor.author
Casartelli, Chiara
dc.contributor.author
Tommasi, Chiara
dc.contributor.author
Lazzarin, Alessandro
dc.contributor.author
Corianò, Matilde
dc.contributor.author
Tornali, C.
dc.contributor.author
Serra, Olga
dc.contributor.author
Gutiérrez-Enríquez, Sara
dc.contributor.author
Llop-Guevara, Alba
dc.contributor.author
Serra, Violeta
dc.date.accessioned
2025-10-25T05:37:34Z
dc.date.available
2025-10-25T05:37:34Z
dc.date.issued
2024-07-10T12:16:38Z
dc.date.issued
2024-07-10T12:16:38Z
dc.date.issued
2024-07-05
dc.identifier
Casartelli C, Tommasi C, Lazzarin A, Corianò M, Tornali C, Serra O, et al. Functional HRD by RAD51 identifies BRCA1 VUS associated with loss of gene function and response to DNA-damaging agents. ESMO Open. 2024 Jul 5;9(7):103629.
dc.identifier
https://hdl.handle.net/11351/11690
dc.identifier
10.1016/j.esmoop.2024.103629
dc.identifier.uri
http://hdl.handle.net/11351/11690
dc.description.abstract
Gene function; DNA
dc.description.abstract
Función genética; ADN
dc.description.abstract
Funció genètica; ADN
dc.description.abstract
This work was supported by European Society for Medical Oncology to BP (no grant number) and ERA-NET Cofund [ERAPERMED 2019–215 to VS].
dc.format
application/pdf
dc.relation
ESMO Open;9(7)
dc.relation
https://doi.org/10.1016/j.esmoop.2024.103629
dc.relation
info:eu-repo/grantAgreement/ES/PE2017-2020/PI19%2F01303
dc.relation
info:eu-repo/grantAgreement/ES/PEICTI2021-2023/PI22%2F01200
dc.rights
Attribution-NonCommercial-NoDerivatives 4.0 International
dc.rights
http://creativecommons.org/licenses/by-nc-nd/4.0/
dc.rights
info:eu-repo/semantics/openAccess
dc.subject
Càncer - Aspectes genètics
dc.subject
Medicaments antineoplàstics - Ús terapèutic
dc.subject
Cromosomes humans - Anomalies - Diagnòstic
dc.subject
ANALYTICAL, DIAGNOSTIC AND THERAPEUTIC TECHNIQUES, AND EQUIPMENT::Diagnosis::Diagnostic Techniques and Procedures::Clinical Laboratory Techniques::Genetic Testing
dc.subject
PHENOMENA AND PROCESSES::Genetic Phenomena::DNA Damage
dc.subject
DISEASES::Neoplasms
dc.subject
CHEMICALS AND DRUGS::Chemical Actions and Uses::Pharmacologic Actions::Therapeutic Uses::Antineoplastic Agents
dc.subject
TÉCNICAS Y EQUIPOS ANALÍTICOS, DIAGNÓSTICOS Y TERAPÉUTICOS::diagnóstico::técnicas y procedimientos diagnósticos::técnicas de laboratorio clínico::pruebas genéticas
dc.subject
FENÓMENOS Y PROCESOS::fenómenos genéticos::daño del ADN
dc.subject
ENFERMEDADES::neoplasias
dc.subject
COMPUESTOS QUÍMICOS Y DROGAS::acciones y usos químicos::acciones farmacológicas::usos terapéuticos::antineoplásicos
dc.title
Functional HRD by RAD51 identifies BRCA1 VUS associated with loss of gene function and response to DNA-damaging agents
dc.type
info:eu-repo/semantics/article
dc.type
info:eu-repo/semantics/publishedVersion
